These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12947081)

  • 1. Treatment for asymptomatic anthracycline-induced cardiac dysfunction in childhood cancer survivors: the need for evidence.
    van Dalen EC; van der Pal HJ; van den Bos C; Caron HN; Kremer LC
    J Clin Oncol; 2003 Sep; 21(17):3377; author reply 3377-8. PubMed ID: 12947081
    [No Abstract]   [Full Text] [Related]  

  • 2. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anthracycline-induced cardiac toxicity more likely in underweight childhood cancer survivors.
    Andolina JR; Dilley K
    J Pediatr Hematol Oncol; 2010 Jul; 32(5):411-5. PubMed ID: 20495481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
    van Dalen EC; van den Brug M; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthracycline associated cardiac toxicity in children with malignancies.
    Mohta R; Saxena A; Jain Y; Gupta S; Thavaraj V; Narain S; Arya LS
    Indian Pediatr; 2002 Jun; 39(6):549-55. PubMed ID: 12084948
    [No Abstract]   [Full Text] [Related]  

  • 6. Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer.
    Guldner L; Haddy N; Pein F; Diallo I; Shamsaldin A; Dahan M; Lebidois J; Merlet P; Villain E; Sidi D; Sakiroglu O; Hartmann O; Leftakopoulos D; de Vathaire F
    Radiother Oncol; 2006 Oct; 81(1):47-56. PubMed ID: 16989913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A drug for prevention of anthracycline-induced cardiac toxicity.
    Med Lett Drugs Ther; 1991 Sep; 33(852):85-6. PubMed ID: 1908544
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cardiologic sequelae of cytostatic therapy].
    Mladosievivcová B
    Cas Lek Cesk; 2001 Mar; 140(5):138-41. PubMed ID: 11347200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Childhood cancer, anthracyclines, and the heart.
    Lancet; 1992 Jun; 339(8806):1388-9. PubMed ID: 1350811
    [No Abstract]   [Full Text] [Related]  

  • 11. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anthracycline cardiotoxicity: review].
    Ribera JM; Montserrat E; Rozman C
    Sangre (Barc); 1983; 28(1):54-68. PubMed ID: 6346540
    [No Abstract]   [Full Text] [Related]  

  • 14. Anthracycline cardiotoxicity: new insights.
    Mushlin PS; Olson RD
    Ration Drug Ther; 1988 Dec; 22(12):1-9. PubMed ID: 3256005
    [No Abstract]   [Full Text] [Related]  

  • 15. Prospective monitoring for anthracycline cardiotoxicity: an introduction.
    McGuire WP
    Cancer Treat Rep; 1978 Jun; 62(6):855. PubMed ID: 667858
    [No Abstract]   [Full Text] [Related]  

  • 16. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children.
    Aggarwal S; Pettersen MD; Bhambhani K; Gurczynski J; Thomas R; L'Ecuyer T
    Pediatr Blood Cancer; 2007 Nov; 49(6):812-6. PubMed ID: 17171687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathology of radiation and anthracycline cardiotoxicity.
    Berry GJ; Jorden M
    Pediatr Blood Cancer; 2005 Jun; 44(7):630-7. PubMed ID: 15825155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Cardiac complications observed during treatment with rubidomycin].
    Macrez C; Marneffe-Lebrequier H; Ripault J; Clauvel JP; Jacquillat C; Weil M
    Pathol Biol; 1967 Oct; 15(19):949-53. PubMed ID: 4869773
    [No Abstract]   [Full Text] [Related]  

  • 19. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention.
    Adams MJ; Lipshultz SE
    Pediatr Blood Cancer; 2005 Jun; 44(7):600-6. PubMed ID: 15856486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.